drugset / Trial / NCT02468193

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

NCT02468193

Phase 2 Completed 9 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The study aim was to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.

Timeline

Start
2015-09-24
Primary completion
2018-06-07
Completion
2018-10-29

Drugs

EvaluationDrugModalityDoseRoute
Subject osilodrostat Small molecule 1 mg Oral
Subject osilodrostat Small molecule 5 mg Oral
Subject osilodrostat Small molecule 10 mg Oral